Literature DB >> 1185200

Cognitive deficits associated with chronic hepatic encephalopathy and their response to levodopa.

A Elithorn, M Lunzer, J Weinman.   

Abstract

A battery of computer-based psychological tests given to seven patients with chronic hepatic encephalopathy showed them to be intellectually impaired, particularly on speed-based measures, as compared with general hospital patients and with patients with cirrhosis but without clinical or electroencephalographic evidence of encephalopathy. Two of the seven patients in the latter group also showed evidence of cognitive impairment on some tests. The effects of levodopa were also evaluated by sequential assessment with these tests. Although there was some improvement in speed of performance on certain tasks and a suggestion of deterioration on other measures, there was little overall change. It is concluded that levodopa has an 'arousing' or antidepressant action and that its effect on intellectual functions is secondary to this alerting effect and is consequently dependent on the emotional and attentional status of the patient.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185200      PMCID: PMC492074          DOI: 10.1136/jnnp.38.8.794

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  Letter: Long term mental changes in levodopa-treated patients.

Authors:  M I Botez; A Barbeau
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

2.  L-dopa in senile dementia.

Authors:  M H Van Woert; G Heninger; U Rathey; M B Bowers
Journal:  Lancet       Date:  1970-03-14       Impact factor: 79.321

3.  Encephalopathy after portacaval anastomosis.

Authors:  A E Read; C F McCarthy; A B Ajdukiewicz; G J Brown
Journal:  Lancet       Date:  1968-11-09       Impact factor: 79.321

4.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

5.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

6.  Long-range motor performance changes in levodopa-treated patients with Parkinson's disease.

Authors:  J H Birdsong; A S McKinney
Journal:  Neurology       Date:  1974-02       Impact factor: 9.910

7.  Mental effects of high-dosage levodopa.

Authors:  C P O'Brien; J N DiGiacomo; S Fahn; G A Schwarz
Journal:  Arch Gen Psychiatry       Date:  1971-01

8.  L-dopa and arousal.

Authors:  T B Horvath; R A Meares
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

9.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

10.  Treatment of chronic hepatic encephalopathy with levodopa.

Authors:  M Lunzer; I M James; J Weinman; S Sherlock
Journal:  Gut       Date:  1974-07       Impact factor: 23.059

View more
  9 in total

1.  Neuropsychological aspects of portal-systemic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

2.  Recognition memory in Parkinson's disease.

Authors:  K A Flowers; I Pearce; J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

3.  The effect of Parkinson's disease on the ability to maintain a mental set.

Authors:  K A Flowers; C Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

Review 4.  Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.

Authors:  Carmina Montoliu; Regina Rodrigo; Pilar Monfort; Marta Llansola; Omar Cauli; Jordi Boix; Nisrin Elmlili; Ana Agusti; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2010-03-02       Impact factor: 3.584

5.  Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.

Authors:  H Schomerus; W Hamster; H Blunck; U Reinhard; K Mayer; W Dölle
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

6.  [Branched-chain amino acids in the treatment of latent porto-systemic encephalopathy. A placebo-controlled double-blind cross-over study].

Authors:  E H Egberts; H Schomerus; W Hamster; P Jürgens
Journal:  Z Ernahrungswiss       Date:  1986-03

7.  Hypothalamic-pituitary dopaminergic function in hepatic failure in man.

Authors:  S Lal; M Oravec; A Aronoff; M E Kiely; H Guyda; S Solomon; N P Nair
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

Review 8.  Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function.

Authors:  Ilhuicamina Daniel Limón; Isael Angulo-Cruz; Lesli Sánchez-Abdon; Aleidy Patricio-Martínez
Journal:  Front Neurosci       Date:  2021-01-27       Impact factor: 4.677

9.  Pharmacological manipulation of cyclic GMP levels in brain restores learning ability in animal models of hepatic encephalopathy: therapeutic implications.

Authors:  Regina Rodrigo; Pilar Monfort; Omar Cauli; Slaven Erceg; Vicente Felipo
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.